CAIRO5 RCT: No overall survival benefit was found for different induction regimens in patients with initially unresectable colorectal cancer liver metastases; FOLFOX/FOLFIRI plus bevacizumab is recommended. https://ja.ma/4eN4svf
JAMA Oncology
图书期刊出版业
Chicago，Illinois 36,970 位关注者
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
关于我们
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- 网站
-
https://jamanetwork.com/journals/jamaoncology
JAMA Oncology的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 5,001-10,000 人
- 总部
- Chicago，Illinois
- 创立
- 2015
- 领域
- Oncology
动态
-
Listen to an interview with Hagop Kantarjian author of "Olverembatinib After Failure of TKIs, Including Ponatinib or Asciminib: A Phase 1b/2 Randomized Clinical Trial in CML" hosted by Vivek Subbiah. https://ja.ma/4eFAjhI
-
-
Olverembatinib, a third-generation BCR-ABL1 TKI, is well-tolerated and effective in treating chronic myeloid leukemia (CML) with resistance to or intolerance of previous TKIs. https://ja.ma/3ZeyfZj
-
-
Most viewed in the last 7 days from JAMA Oncology: Prostate cancer treatment was associated with higher rates of complications in the 12 years after treatment, even after accounting for age-related symptoms and disease. https://ja.ma/4fsdPSd
-
-
Viewpoint discusses the importance of hormone deprivation–free survival as an end point for both men with prostate cancer and women with breast cancer. https://ja.ma/40CMXL4
-
-
This cohort study defines clinical and genetic risk factors for ICI-induced diabetes, highlighting phenotypic heterogeneity and implications for personalized immunotherapy. https://ja.ma/4hAARYJ
-
-
Viewpoint discusses the clinical vs economic success of MRI combined with linear accelerator technology and its impact on patients. https://ja.ma/3YRrqNb
-
-
An analysis of cancer drugs granted accelerated approval in the US revealed that two-thirds were also approved in the EU, and nearly half of those lack a verified clinical benefit in terms of overall survival or quality of life. https://ja.ma/4hKB4sr
-
-
Most viewed in the last 7 days from JAMA Oncology: Prostate cancer treatment was associated with higher rates of complications in the 12 years after treatment, even after accounting for age-related symptoms and disease. https://ja.ma/4i1BAT8
-
-
In this Special Communication, three strategies are proposed to make cancer drugs more accessible and affordable in low- and middle-income countries. https://ja.ma/3USQSPU
-